BDBM621115 US20230303563, Compound 117

SMILES OCc1cc2ncc(-c3cccc(N[C@H]4CNC[C@@H]4F)n3)n2cc1C1CC1

InChI Key InChIKey=WMZGRDMNDXPHMF-UHFFFAOYSA-N

Data  3 IC50  11 Kd

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 621115   

TargetInterleukin-1 receptor-associated kinase 1(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataIC50: 5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataIC50: 0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataIC50: 0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0240nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835H](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0380nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0110nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0770nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.160nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.00700nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0120nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [K663Q](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.190nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0510nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [R834Q](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0610nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [572-603](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.430nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent